Original research

Incidence and duration of incident oropharyngeal gonorrhoea and chlamydia infections among men who have sex with men: prospective cohort study

Eric P F Chow ,^{1,2,3} Lenka A Vodstrcil ,^{1,2} Deborah A Williamson ,⁴ Kate Maddaford ,¹ Jane S Hocking,³ Melinda Ashcroft ,⁴ Vesna De Petra,⁴ Catriona S Bradshaw,^{1,2,3} Christopher K Fairley ,^{1,2}

ABSTRACT

¹Melbourne Sexual Health

Melbourne, Victoria, Australia

²Central Clinical School, Monash

University, Melbourne, Victoria,

³Centre for Epidemiology

School of Population and

and Biostatistics. Melbourne

Global Health, The University of

Melbourne, Melborune, Victoria,

⁴Microbiological Diagnostic

Unit Public Health Laboratory,

Immunology, The University of

Immunity, Melbourne, Victoria,

Institute for Infection and

Correspondence to

Associate Professor Eric P F

Monash University, Carlton,

EPFC and LAV are joint first

Received 31 August 2020

Revised 18 October 2020

Accepted 25 October 2020

Check for updates

© Author(s) (or their

employer(s)) 2020. No

To cite: Chow EPF,

Williamson DA, et al.

Sex Transm Infect Epub ahead

of print: [*please include* Day Month Year]. doi:10.1136/

sextrans-2020-054764

Vodstrcil LA.

commercial re-use. See rights

and permissions. Published

Chow, Central Clinical School,

Victoria, Australia; eric.chow@

Melbourne at The Peter Doherty

Department of Microbiology and

Centre, Alfred Health,

Australia

Australia

Australia

monash.edu

authors.

Objectives This prospective cohort study aimed to determine the natural history and incidence of oropharyngeal gonorrhoea and chlamydia among a cohort of men who have sex with men (MSM) over a 12week period, and to examine risk factors associated with incident oropharyngeal infections.

Methods MSM either aged ≥18 years and had a diagnosis of oropharyngeal gonorrhoea by nucleic acid amplification test (NAAT) in the past 3 months or aged 18–35 years who were HIV-negative taking pre-exposure prophylaxis (PrEP) were eligible for this study. Enrolled men were followed up for 12 weeks. Oropharyngeal swabs were collected at week 0 (baseline) and week 12 (end of study). Between these time points, weekly saliva specimens and the number of tongue kissing, penile—oral and insertive rimming partners were collected by post. Oropharyngeal swabs and saliva specimens were tested by NAAT for *Neisseria gonorrhoeae* and *Chlamydia trachomatis*. Poisson regression was performed to examine the risk factors (weekly number of partners) associated with incident oropharyngeal gonorrhoea.

Results A total of 100 MSM were recruited. The incidence of oropharyngeal gonorrhoea and chlamydia was 62 (95% CI 37 to 105) and 9 (95% CI 2 to 35)/100 person-years, respectively. The median duration of incident oropharyngeal infection with gonorrhoea was 28 days (IQR=21–36, n=7). The incidence rate ratio (IRR) for oropharyngeal gonorrhoea increased with an increased number of kissing partners (IRR=1.08; 95% CI 1.03 to 1.12) an increased number of penile-oral sex partners (IRR=1.07, 95% CI 1.01 to 1.14) but not with an increased number of insertive rimming partners (IRR=1.11, 95% CI 0.96 to 1.29) or other demographic factors. The IRR and duration of incident oropharyngeal chlamydia were not calculated due to the small number of cases (n=2).

Conclusions MSM have a high incidence of oropharyngeal gonorrhoea and the median duration of infection was less than 3 months.

INTRODUCTION

Men who have sex with men (MSM) are disproportionally affected by gonorrhoea, although more recently, cases have also been rising in heterosexuals.¹ The rising number of cases is not only

expensive for the health system but also increases the probability of *Neisseria gonorrhoeae* developing resistance.² This increased potential for resistance is why the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have described the rises in gonorrhoea and their resistant potential as an urgent health threat.³⁴ To combat this threat, both organisations specifically called for improved control of gonorrhoea.

The successful control of gonorrhoea in MSM will be challenging in the current environment because condom use has declined substantially with the introduction of biomedical interventions for HIV control in the late 2010s.¹⁵ The proportion of Australian MSM who have had condomless anal sex with casual partners in the past 6 months increased significantly from 35% in 2014 to 56% in 2018.¹ Accessible healthcare can provide timely diagnosis and treatment for individuals and therefore can reduce ongoing transmission.¹ While accessible healthcare works particularly well for symptomatic STIs because the symptoms prompt infected individuals to seek treatment, accessible healthcare is less effective for asymptomatic infections.⁶ Among heterosexuals, the genitals are the primary site of gonorrhoea infection and these sites are associated with symptoms.^{7–9} In MSM, the oropharynx or anorectum are the primary sites of infection (sites that are frequently associated with no symptoms),¹⁰ suggesting that accessible healthcare will be a less effective control strategy in asymptomatic MSM.

To investigate the difficulty in controlling gonorrhoea in MSM, researchers have proposed new transmission routes.^{11 12} The findings have highlighted how common gonorrhoea is at the extragenital sites in MSM, particularly at the oropharynx, which has been proposed as an important site for driving onward transmission.¹¹ Further, studies have also shown that both N. gonorrhoeae and Chlamydia trachomatis can be detected in saliva,^{13 14} suggesting these infections can be transmitted via saliva exchange and activities traditionally considered to be low risk, such as kissing.¹⁵ We conducted this longitudinal study to determine the natural history and incidence of oropharyngeal gonorrhoea and chlamydia among a cohort of MSM over a 12-week period to examine risk factors associated with the incident oropharyngeal infections.

BMJ

by BMJ.

MATERIALS AND METHODS

The Gonorrhoea Incidence (GIN) Study was a prospective cohort study of MSM over a 12-week period. Between 15 August 2019 and 30 October 2019, we recruited 100 MSM at the Melbourne Sexual Health Centre (MSHC), Australia. The final visit of the last participant occurred on 29 January 2020. Men were eligible if they had sufficient English language proficiency to understand the study procedure and requirement and were aged ≥ 18 years and had a diagnosis of oropharyngeal gonorrhoea by nucleic acid amplification test (NAAT) in the past 3 months; or aged 18-35 years who were HIV-negative taking HIV pre-exposure prophylaxis (PrEP); or reported having at least one casual partner in the past 3 months if not taking PrEP. These eligibility criteria were selected because men in these groups were at a higher risk of acquiring gonorrhoea.^{16 17} Men were not eligible if they were unable to complete the 12-week follow-up, reported ongoing use of antibiotics for 2 weeks or more or were already enrolled in another clinical trial involving the use of antibiotics. MSM living with HIV were also eligible for the study.

The GIN study consisted of two clinic visits over a 12-week period: week 0 (baseline) and week 12 (end of study). To provide increased flexibility, we allowed men to attend the week 12 clinic visit between 11 (minimum) and 14 (maximum) weeks from recruitment. Participants who did not attend the clinic after week 14 were considered as lost to follow-up. Enrolled men were asked to provide clinician-collected oropharyngeal swab and self-collected saliva specimens at weeks 0 and 12, and weekly saliva specimens by the post during the study period. Gonorrhoea and chlamydia screening at all three sites (ie, urethral, oropharyngeal and anorectal) were also offered to all men at week 12. Men who tested positive for N. gonorrhoeae or C. trachomatis at week 0 or 12 were treated at the time of diagnosis according to the standard of care in accordance with the Australian guidelines.¹⁸ Men were instructed to self-collect their saliva sample at home weekly from weeks 1 to 11 during the study period and to post the samples to MSHC by mail. A weekly short message service (SMS) was sent to the participant to remind them to send the saliva sample. Participants were advised to accumulate saliva in the mouth for about 30s and then spit into a specimen jar, then collect the saliva using the UriSwab (Copan Diagnostics, Brescia, Italy). All oropharyngeal swabs and saliva samples were tested by NAAT using Aptima Combo 2 assay (Hologic Panther System; Hologic, San Diego, California, USA). UriSwabs have been successfully used for N. gonorrhoeae or C. trachomatis testing by NAAT in urine and saliva specimens.¹⁴ ^{19–21} All oropharyngeal swabs (weeks 0 and 12) were tested in real time, and participants were treated with standardof-care antibiotics. Saliva samples were stored at -80° C until the end of the study and were batched tested in accordance with the human research and ethics approval for this study; results were not provided to the participants. Participants were required to complete a self-administered paper-based questionnaire each week that asked about the number of men they tongue-kissed, performed penile-oral sex (ie, the participant's sex partner put his penis in the participant's mouth) and performed insertive rimming (ie, the participant's mouth touched and/or licked his partner's anus) in the past 7 days. The use of any antibiotics and sexual practices in the past 3 months were asked at weeks 0 and 12. All men who tested positive for any STI received standard recommended treatment. Men received an AUD\$10 (USD\$7) voucher per saliva sample to a maximum of AUD\$110 (USD\$80) if they sent all saliva samples between weeks 1 and 11 to compensate for their time.

An incident gonorrhoea or chlamydia case was defined as a positive NAAT test from an oropharyngeal swab or saliva sample following a prior negative result during the study period. We excluded week 0 (baseline) positive oropharyngeal gonorrhoea and chlamydia tests, and all these men were treated before they continued in the study. The person-years were calculated from the date of the first sample collected to the date of the last sample. The incidence rate was defined as the number of incident cases per 100 person-years, and the subsequent weeks were excluded if oropharyngeal gonorrhoea continued to be detected. A person could be diagnosed with two incident infections if there were at least two negative results in between positive results. Any equivocal results were considered as positive if there was a positive result in the previous or following week. The duration of an incident infection was defined as the number of days from the date of first positive or equivocal result to the date of the subsequent negative result or the date receiving treatment, excluding men who tested positive only at the week 12 visit. The median duration of incident oropharyngeal chlamydia infections was not calculated due to a small number of incident cases in this cohort (ie, two cases), and we reported each case separately. Poisson regression was performed to examine the risk factors associated with incident oropharyngeal gonorrhoea; the incidence rate ratios (IRRs) and corresponding 95% CIs were reported. Spearman's correlation was performed between the number of weekly tongue kissing, penile-oral and rimming partners. All statistical analyses were performed using STATA V.14.

RESULTS

A total of 125 men were referred to the research team. We excluded 25 men who were not eligible: 6 did not have any casual partners; 12 were unable to comply with the study protocol requirements due to travel; 4 declined to participate; 2 reported ongoing antibiotics use for 2 weeks or more; and 1 was enrolled in another clinical trial. The remaining 100 men who met the inclusion criteria were enrolled in the study and had a median age of 30 years (IQR=26-33 years). Most participants were HIV-negative men taking PrEP (n=89, 89%), followed by HIVnegative men not taking PrEP (n=9, 9%), with only two men living with HIV (n=2, 2%). There were 22 (22%) men who had a diagnosis of oropharyngeal gonorrhoea 3 months before enrolment. At week 0, men reported a median of 9 (IQR=5-15) male partners in the past 3 months, including a median of 8 (IQR=4-15) tongue-kissing partners, 5 (IQR=3-10) penile-oral sex partners and 2 (IQR=2-6) insertive rimming partners 3 months before enrolment. Ninety-five (95%) men completed the week 12 clinic visit (figure 1). A total of 1162 saliva samples (range of 3-13 per person, including enrolment samples) and 195 oropharyngeal swabs (including enrolment samples) were collected and tested. There was a total of 22 person-years of observation. Men had a median of one (or mean=2) kissing partner, a median of one (or mean=2) oral sex partner and a median of zero (or mean=1) insertive rimming partner each week during the study. Each of these three practices were strongly correlated with each other with correlation coefficients of between 0.50 and 0.80 (see online supplemental figure 1). The concordance for the saliva sample and swab specimens was relatively high at enrolment but less so at week 12 (see online supplemental tables 1–4).

At week 0, 16 men (16%, 95% CI 9% to 25%) tested positive for *N. gonorrhoeae* and 3 (3%, 95% CI 1% to 9%) tested positive for *C. trachomatis* from either the oropharyngeal swabs or saliva samples. Two (95% CI 0% to 7%) men had infectious syphilis diagnosed at week 0. All infections detected at week 0 were




Figure 1 Study flowchart. GIN, Gonorrhoea Incidence; MSM, men who have sex with men. *Note. 75 men returned 11 weekly swabs OR returned 10 swabs because they attended for their final visit in week 11 due to scheduling their 3 month visit as permitted.*

treated and men only contributed person-time to the overall incidence rates post-treatment.

During the 12 weeks of follow-up, there were 14 incident oropharyngeal gonorrhoea diagnoses in 12 men, and the overall incidence of oropharyngeal gonorrhoea was 62.43 (95% CI 36.97 to 105.41) per 100 person-years. Of the 14 incident infections, 8 were detected on weekly saliva samples (between weeks 1 and 11), and 4 cases were only detected on the oropharyngeal swabs at week 12 (figure 2). Eight men had infection detected on saliva samples between weeks 1 and 11. One man collected his saliva sample only 3 days before his week 12 visit, and therefore, he was excluded from the calculation of the duration of incident infection (participant 6, figure 2). The median duration that incident oropharyngeal gonorrhoea persisted for was 28 days (IQR=21-36, n=7) (figure 3).

The IRR for oropharyngeal gonorrhoea increased with increased number of kissing partners (IRR=1.08, 95% CI 1.03 to 1.12, p=0.001) and increased number of penile-oral sex partners (IRR=1.07; 95% CI 1.01 to 1.14; p=0.016) but not with increased number of insertive rimming partners (IRR=1.11, 95% CI 0.95 to 1.29, p=0.175) or other demographic factors (table 1). Of the 14 incident oropharyngeal gonorrhoea cases, all men (100%) reported kissing in prior week, while two (14%) had kissing only with no penile-oral sex and insertive rimming; six (43%) had kissing and penile-oral sex but no rimming; and the remaining six (43%) had kissing, penile-oral sex and rimming. There were 69 men reporting 244 weekly intervals with no kissing partners, of which 15 weekly intervals were with penile-oral sex partners and 4 weekly intervals were with insertive rimming partners; however, none tested positive for N. gonorrhoeae in the saliva or oropharynx. In contrast, there were 80 men reporting 349 weekly intervals with no penile-oral sex partners, of which 120 weekly intervals were with kissing partners and 27 weekly intervals were with insertive rimming partners; 2 men tested positive for N. gonorrhoeae in the saliva or oropharynx. Furthermore, there were 92 men reporting 683 weekly intervals with no insertive rimming partners, of which 94 weekly intervals were with kissing partners and 12 weekly intervals were with penile-oral sex partners; 6 men tested positive for *N. gonorrhoeae* in the saliva or oropharynx, 1 of whom had a second incident infection.

There were two incident oropharyngeal chlamydia diagnoses in two men, and the overall incidence of oropharyngeal chlamydia was 8.85 (95% CI 2.21 to 35.39) per 100 person-years. Of the two incident infections, both were detected on weekly saliva samples: one was detected at week 4 and then tested negative at week 5, and the second was tested positive on three consecutive saliva samples from weeks 10–12 as well as his week 12 oropharyngeal swab.

There were 7 cases of incident anorectal gonorrhoea, 2 cases of incident urethral gonorrhoea (figure 3), 10 cases of incident anorectal chlamydia, 5 cases of incident urethral chlamydia and 3 cases of infectious syphilis (2 primary and 1 early latent).

DISCUSSION

We estimated that incidence of oropharyngeal infection in this cohort was more than 60% per year, and about half of the cases were detected first on saliva samples between week 0 and week 12. Furthermore, the estimated median duration of incident oropharyngeal gonorrhoeal infection was 28 days, consistent with past studies showing oropharyngeal gonorrhoeal infection has a relatively short duration.^{22 23} Incident oropharyngeal gonorrhoea was associated with exposure to a partner's mouth (ie, kissing) or penis (ie, penile-oral sex) but not their partner's anus (ie, rimming) in the previous week. Unfortunately, separating the independent contribution of the different exposures is challenging because exposure to these three sites commonly occurs together in the same sexual act.^{24 25} There has been only one similar study published in abstract form that reported a high incidence of oropharyngeal gonorrhoea of about 35% per year based on weekly oropharyngeal swab sampling; however, no data on sexual risk were provided.²² Our data suggest that the true incidence of oropharyngeal gonorrhoea is higher than what has been previously appreciated even when screening occurs every 3 months. When considering the number of exposures to different mouths, penises and anuses and the prevalence of gonorrhoea at each site, it is challenging to see how penises alone could be responsible for this high incidence of oropharyngeal gonorrhoea.¹¹

Our study had several limitations. First, we used saliva samples that were sent through the postal service to avoid the men needing to return to the clinic every week for an oropharyngeal swab. This strategy did allow us to have a very high return rate (95%), but saliva appeared to be considerably less sensitive for oropharyngeal gonorrhoea than a throat swab using the Aptima combo that tests for RNA. However, our previous studies using DNA detection suggested saliva testing for gonorrhoea was quite sensitive for the detection of N. gonorrhoeae and comparable with the detection using oropharyngeal swabs.¹³ This suggests that it is likely that we have underestimated the true incidence and duration of infection for oropharyngeal gonorrhoea in this study. Further studies are required to determine the optimal testing and sampling for saliva samples for the detection of N. gonorrhoeae. Second, the study was conducted around winter and spring seasons. STI cases peak around summer, and therefore, we might have underestimated the incidence due to the seasonal variations of STI and sexual practices.^{26 27} Third, we specifically chose men who were likely to have a high incidence of oropharyngeal gonorrhoea, and thus, our estimate may not be generalised to the entire MSM population. Our population, for example, had nine partners in the past 3 months, which is about three times higher than our entire clinic population, which

(A)														
	Week													
ID	0	1	2	3	4	5	6	7	8	9	10	11	12	
1					S	S	S, O	S *						
2											S	S	S, O	
3													0	
4							S	S	S	S				
5					S	S	S	S	S	S	S		0	
6												S	S, O	
7													0	
8								S					0, A	
9						S	S		S				0, A	
10													0, A, U	
11			S	S									0	
12								S	S	S	S	S, O	*	

(B)

	Week												
ID	0	1	2	3	4	5	6	7	8	9	10	11	12
13		S			S								

1	C)	
۱	C)	

		Week											
ID	0	1	2	3	4	5	6	7	8	9	10	11	12
14													А
15	0 <i>,</i> A	*						А	*				
16													А
17	А	*											A, U

Legend:

Negative NAAT result Positive NAAT result

Equivocal NAAT result

Invalid NAAT result No sample

S = Saliva sample

O = Oropharyngeal swab

A = Anorectal swab

U= Urine specimen

* = Treatment given. Participants tested positive at week 12 received treatment at week 13 (after the study period)

Figure 2 Incident gonorrhoea cases among (A) 12 men tested positive for *Neisseria gonorrhoeae* in the saliva or the oropharynx; (B) 1 man with equivocal results for *N. gonorrhoeae* in the saliva; and (C) 4 men tested positive for *N. gonorrhoeae* at other anatomical sites except for the oropharynx. ID, identification number; NAAT, nucleic acid amplification test. *Note. The ID numbers were recorded forpublication and they were not the actual study ID. Participant 1 had anoropharyngeal swab taken at week 6 as he presented to the clinic as a contact of infection. He presented with symptoms including sore throat, dysuria andclear urethral discharge. He was tested positive for oropharyngeal gonorrhoeaand urethral Mycoplasmagenitalium. Participant 15 had an anorectalswab at week 7 and tested positive for anorectal gonorrhoea. He presented to the clinic as a contact of infection but did not have any symptoms on the day.*






Figure 3 Kaplan-Meier curve of the duration of incident oropharyngeal gonorrhoea infection. CI, confidence intervals.

is about three partners every 3 months.²⁸ We estimated that the incidence of urethral gonorrhoea (8/100 person-years) and syphilis (12/100 person-year) in our study was similar to that of a large study of MSM taking PrEP in Melbourne (the "PrEPX" study).²⁹ However, the estimated incidence of oropharyngeal gonorrhoea in the present study (55/100 person-year) was nearly threefold higher than the PrEPX study (20/100 person-years) and suggests that cases in the PrEPX study were missed because sampling occurred only every 3 months. Finally, 4 out of 12 men had their incident oropharyngeal *N. gonorrhoeae* infection detected at the week 12 visit only, and so we might have underestimated the duration of the infection's persistence due to the short follow-up time of 12 weeks in our study.

To our best knowledge, there has been only one study sampling MSM weekly for the detection of *N. gonorrhoeae* in the oropharynx that was conducted in the USA.²² The study recruited 140 men who self-collect oropharyngeal swabs at home over a 48-week period, but only 48 (34%) men were included in the final analysis. The study estimated the incidence of oropharyngeal gonorrhoea was 35/100 person-years, which is lower than the estimate in our study. Both Barbee's and our studies report an incidence of oropharyngeal gonorrhoea that is substantially higher than the incidence seen in other studies, including cohort

studies of PrEP participants. Furthermore, Barbee *et al*²² estimated that the median duration of oropharyngeal gonorrhoea infection was 9 weeks (95% CI 3 to 19), which was longer than our estimate of 4 weeks. The difference between the two studies is likely due to the limited sensitivity of posted saliva samples tested by RNA in our study. However, both Barbee's and our study do suggest that the incidence of oropharyngeal gonorrhoea is substantially higher than what has previously been appreciated and that some infections are short-lived and would have been missed with 3 monthly screenings.²²

Our study raises questions about the currently accepted routes of transmission for gonorrhoea that dictate that oropharyngeal gonorrhoea is predominantly acquired from urethral infection following oral sex. In our study, oropharyngeal gonorrhoea was associated with exposure in the previous week to both a partner's mouth or penis but not the anus. This is consistent with a previous study showing having kissing-only partners is an independent risk factor for oropharyngeal gonorrhoea.¹⁵ We note that separating the individual contribution is statistically impossible when collinearity is so high. However, we did find that there were no oropharyngeal cases in men with no kissing partners in the previous week, yet among men with no oral sex partners, six oropharyngeal infections occurred and among men with no rimming partners, seven oropharyngeal cases occurred. We also had only two cases of urethral gonorrhoea occur in the men, and both presented with urethral symptoms, suggesting that the prevalence of urethral gonorrhoea in men like the ones in our study would be very low. In contrast, the proportion of men who had oropharyngeal gonorrhoea detected in the oropharynx at week 0 or 12 was more than 10%, indicating that the urethra is unlikely to be the sole source of the high incidence of oropharyngeal gonorrhoea we observed.

We found a substantially lower incidence of chlamydial infection in the oropharynx of only about 9/100 person-years despite a considerable incidence of urethral (20/100 person-years) and particularly anorectal infection (40/100 person-years), although the latter two sites were solely based on samples taken at week 12. In Barbee's study, they collected weekly oropharyngeal and anorectal samples for chlamydia and found an incidence of anorectal chlamydia of 59/100 years but the incidence of oropharyngeal chlamydia was not reported.²² Taken together, these data suggest that the oropharynx plays a substantially less important role for chlamydia than for gonorrhoea.

Characteristic	n (%)	Events	PY	Incidence rate	Crude IRR	95% CI	P value*
Age (years), median (IQR)	30 (26–33)	_	-	_	1.02	0.94 to 1.11	0.614
Oropharyngeal gonorrhoea in the past 3 month	IS						
No	78 (78)	10	17	57.66	1 (ref)	-	-
Yes	22 (22)	2	5	42.87	1.04	0.30 to 3.58	0.952
HIV status and PrEP use							
HIV negative not on PrEP	89 (89)	2	2	112.04	1 (ref)	-	-
HIV negative on PrEP	9 (9)	12	20	50.69	0.49	0.12 to 1.95	0.312
HIV positive†	2 (2)	0	0.5	0	N/A	N/A	N/A
Weekly sexual practices							
Number of kissing partners‡	-	-	-	-	1.08	1.03 to 1.12	0.001
Number of penile-oral sex partners‡	-	-	-	-	1.07	1.01 to 1.14	0.016
Number of insertive rimming partners‡	-	-	-	-	1.11	0.96 to 1.29	0.175

*P values from Poisson regression.

†The IRR for the two men living with HIV were not calculated because no incident oropharyngeal gonorrhoea cases were observed.

\$Number of partners for each sexual practice assessed as a continuous variable. Data reflect change in IRR per one additional partner.

CI, confidence intervals; HIV, human immunodeficiency virus; IQR, interquartile range; IRR, incidence rate ratio; PrEP, pre-exposure prophylaxis; PY, person years of follow-up.

Epidemiology

To conclude, our results suggested that the incidence of oropharyngeal gonorrhoea was relatively high among MSM predominately taking PrEP and that the duration of infection was short and, some persisted for only a few weeks. This suggests that a 3-monthly screening approach may not be sufficient to control gonorrhoea. The short duration of infection implies that if screening were to be effective, it would need to be very frequent. However, we showed that a considerable number of the infections cleared spontaneously and did not require treatment. Before any recommendation could be made on more frequent screening, further studies would be required to delineate the harms, benefits, cost-effectiveness and adherence to such frequent screening intervals.

Key messages

- Men who have sex with men have a high incidence of oropharyngeal gonorrhoea of 62/100 person-years.
- The median duration of oropharyngeal gonorrhoea infection was short (ie, 28 days).
- The incidence oropharyngeal gonorrhoea was associated with an increased number of kissing partners, penile–oral sex partners but not with insertive rimming partners.

Handling editor Jonathan Ross

Twitter Eric P F Chow @EricPFChow, Lenka A Vodstrcil @lenkavod, Deborah A Williamson @drdebwilliamson, Jane S Hocking @JHocking01, Melinda Ashcroft @ BioMinnie, Catriona S Bradshaw @Cat_Bradshaw_ and Christopher K Fairley @ kitfairley

Contributors EPFC, LAV and CKF conceived and designed the study. EPFC, LAV, KM and CKF designed the study materials. LAV and KM oversaw the ethics approval and study procedures. KM was involved in database management, specimen collection, processing and storage, and performed chart review. LAV performed the statistical analyses. EPFC and JSH assisted with the statistical analyses. EPFC, LAV and CKF wrote the first draft of the manuscript. DW oversaw the laboratory testing results and was assisted by VDP. All authors were involved in revising the manuscript for important intellectual content and approved the final version.

Funding This trial was supported by an Australian National Health and Medical Research Council (NHMRC) Project Grant (No. 568971). CKF and CSB are supported by an NHMRC Leadership Investigator Grant (GNT1172900 and GNT1173361, respectively). DW and EPFC are supported by an Australian NHMRC Emerging Leadership Investigator Grant (GNT1174555 and GNT1172873, respectively). JSH is supported by an NHMRC Senior Research Fellowship (GNT1136117).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Written consent was obtained from all participants before commencing the study. This study was approved by the Alfred Hospital Ethics Committee (272/19).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

ORCID iDs

Eric P F Chow http://orcid.org/0000-0003-1766-0657 Lenka A Vodstrcil http://orcid.org/0000-0003-3679-9195 Deborah A Williamson http://orcid.org/0000-0001-7363-6665 Kate Maddaford http://orcid.org/0000-0001-5213-1289 Melinda Ashcroft http://orcid.org/0000-0001-9157-4533 Christopher K Fairley http://orcid.org/0000-0001-9081-1664

REFERENCES

- Chow EPF, Grulich AE, Fairley CK. Epidemiology and prevention of sexually transmitted infections in men who have sex with men at risk of HIV. *Lancet HIV* 2019;6:e396–405.
- 2 Lahra MM, Dillon J-AR, George CRR, et al. From zero to zero in 100 years: gonococcal antimicrobial resistance. *Microbiol Aust* 2016;37:173–6.

- 3 Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. Atlanta CDC; 2013. https://www.cdc.gov/drugresistance/pdf/ threats-report/2019-ar-threats-report-508.pdf [Accessed 25 August 2020].
- 4 World Health Organization. Global action plan on antimicrobial resistance. Geneva, Switzerland WHO Press, World Health Organization; 2015 [Accessed 25 August 2020]. 9789241509763.
- 5 Holt M, Lea T, Mao L, et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013–17. *Lancet HIV* 2018;5:e448–56.
- 6 Fairley CK, Chow EPF, Hocking JS. Early presentation of symptomatic individuals is critical in controlling sexually transmissible infections. Sex Health 2015;12:181–2.
- 7 Martín-Sánchez M, Ong JJ, Fairley CK, et al. Clinical presentation of asymptomatic and symptomatic heterosexual men who tested positive for urethral gonorrhoea at a sexual health clinic in Melbourne, Australia. BMC Infect Dis 2020;20:486.
- 8 Martín-Sánchez M, Fairley CK, Ong JJ, et al. Clinical presentation of asymptomatic and symptomatic women who tested positive for genital gonorrhoea at a sexual health service in Melbourne, Australia. Epidemiol Infect 2020;148:e240.
- 9 Chow EPF, Chen MY, Williamson DA, et al. Oropharyngeal and genital gonorrhea infections among women and heterosexual men reporting sexual contact with partners with gonorrhea: implication for oropharyngeal testing of heterosexual gonorrhea contacts. Sex Transm Dis 2019;46:743–7.
- 10 Cornelisse VJ, Chow EPF, Huffam S, et al. Increased detection of pharyngeal and rectal gonorrhea in men who have sex with men after transition from culture to nucleic acid amplification testing. Sex Transm Dis 2017;44:114–7.
- 11 Fairley CK, Cornelisse VJ, Hocking JS, *et al*. Models of gonorrhoea transmission from the mouth and saliva. *Lancet Infect Dis* 2019;19:e360–6.
- 12 Fairley CK, Hocking JS, Zhang L, *et al*. Frequent transmission of gonorrhea in men who have sex with men. *Emerg Infect Dis* 2017;23:102–4.
- 13 Chow EPF, Tabrizi SN, Phillips S, et al. Neisseria gonorrhoeae bacterial DNA load in the Pharynges and saliva of men who have sex with men. J Clin Microbiol 2016;54:2485–90.
- 14 Phillips TR, Fairley CK, Maddaford K, et al. Bacterial load of Chlamydia trachomatis in the posterior oropharynx, tonsillar Fossae, and saliva among men who have sex with men with untreated oropharyngeal Chlamydia. J Clin Microbiol 2019;58:e01375-19.
- 15 Chow EPF, Cornelisse VJ, Williamson DA, et al. Kissing may be an important and neglected risk factor for oropharyngeal gonorrhoea: a cross-sectional study in men who have sex with men. Sex Transm Infect 2019;95:516–21.
- 16 Marinelli T, Chow EPF, Tomnay J, et al. Rate of repeat diagnoses in men who have sex with men for Chlamydia trachomatis and Neisseria gonorrhoeae: a retrospective cohort study. Sex Health 2015;12:418–24.
- 17 Ong JJ, Baggaley RC, Wi TE, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. JAMA Netw Open 2019;2:e1917134.
- 18 Australasian Sexual Health Alliance. Australian STI management guidelines for use in primary care Sydney, Australia: Australasian sexual health alliance, 2018. Available: http://www.sti.guidelines.org.au/ [Accessed 25 August 2020].
- 19 Costa A-MG, Garland SM, Guy R, et al. UriSwab: an effective transport medium for nucleic acid detection of Chlamydia trachomatis, Mycoplasma genitalium and Neisseria gonorrhoeae. Sex Health 2017;14:502–6.
- 20 McNicol J, Debattista J. Use of the UriSwab collection device for testing of Chlamydia trachomatis and Neisseria gonorrhoeae: implications for a postal testing service. *Int J STD AIDS* 2013;24:477–80.
- 21 Chow EPF, Walker S, Hocking JS, et al. A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the omega (oral mouthwash use to eradicate gonorrhoea) study protocol. BMC Infect Dis 2017;17:456.
- 22 Barbee L, Soge O, Haglund M, et al. 002.4 incidence and duration of pharyngeal and rectal gonorrhea and Chlamydia among high-risk men who have sex with men (MSM). Sex Transm Infect 2019;95:A40.
- 23 Chow EPF, Camilleri S, Ward C, *et al*. Duration of gonorrhoea and Chlamydia infection at the pharynx and rectum among men who have sex with men: a systematic review. *Sex Health* 2016;13:199–204.
- 24 Rosenberger JG, Reece M, Schick V, *et al*. Sexual behaviors and situational characteristics of most recent male-partnered sexual event among gay and bisexually identified men in the United States. *J Sex Med* 2011;8:3040–50.
- 25 Kilner A, Fairley CK, Burrell S, *et al*. Age pattern of sexual activities with the most recent partner among men who have sex with men in Melbourne, Australia: a crosssectional study. *BMJ Sex Reprod Health* 2020. doi:10.1136/bmjsrh-2020-200720. [Epub ahead of print: 31 Aug 2020].
- 26 Chow EPF, Vodstrcil LA, Fairley CK. Seasonal variations in kissing and sexual activities among men who have sex with men in Melbourne, Australia: implications for seasonal sexually transmissible infection preventions and interventions. *Sex Health* 2020;17:149–54.

- 27 Cornelisse VJ, Chow EPF, Chen MY, et al. Summer heat: a cross-sectional analysis of seasonal differences in sexual behaviour and sexually transmissible diseases in Melbourne, Australia. Sex Transm Infect 2016;92:286–91.
- 28 Priest D, Read TRH, Chen MY, *et al.* Only recent sexual partners contribute to oropharyngeal gonorrhoea positivity: the number of sexual partners over different

time periods as an indicator of gonorrhoea and Chlamydia infection duration among men who have sex with men. *Sex Health* 2018;15:342–9.

29 Traeger MW, Cornelisse VJ, Asselin J, et al. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA 2019;321:1380–90.